Dr. Elena Vasquez
· For research use only. Not for human consumption.
The GLP-2 intestinal crypt proliferation assay is the standard lab test researchers use to measure how much GLP-2 speeds up cell division inside the gut’s tiny repair factories, called crypts (PubMed: GLP-2 crypt proliferation BrdU Ki-67). Think of crypts like pockets at the base of your intestinal lining, packed with stem cells that constantly churn out fresh cells to replace the ones worn away by digestion. GLP-2 is a small protein released by the gut that acts as a growth signal, telling those crypt cells to divide faster. Two staining methods are used to count how many cells responded: BrdU incorporation and Ki-67 staining. Which one a researcher picks depends on exactly what question they are asking. For research use only. Not for human consumption.
The biology shapes the test design. Crypts are organized like an apartment building: stem cells sit at the bottom floors (positions 1–4), their fast-dividing offspring fill the middle floors (positions 5–15), and fully mature cells ride the escalator up to the villus tip before being shed. GLP-2 pushes more cells into that middle fast-dividing zone. BrdU and Ki-67 each spot dividing cells, but they look at different time windows, and they need the tissue prepared differently. For more background, see GLP-2 and Intestinal Biology: What Researchers Study and GLP-2 vs GLP-1: Same Family, Different Functions.
This post walks through how each GLP-2 intestinal crypt proliferation assay works in practice, from tissue prep to counting cells under the microscope, in both animal intestine and lab-grown mini-gut models called organoids. For research use only. Not for human consumption.
TL;DR: The GLP-2 intestinal crypt proliferation assay uses either BrdU (which tags cells caught actively copying DNA) or Ki-67 (which tags all dividing cells at the moment tissue is collected). Both require fixed intestinal tissue that is stained, sectioned, and counted under a microscope. Choosing between them comes down to whether you want a short snapshot of copying activity or a broader count of all cycling cells. For research use only.
Why crypt proliferation is the primary readout for GLP-2 research
GLP-2 does not talk directly to the cells lining the intestine. Instead, GLP-2 receptors sit on nearby support cells, specifically nerve cells and connective-tissue cells just beneath the epithelium. Those support cells pick up the GLP-2 signal and release their own growth factors (including KGF and IGF-1), which then reach the epithelial crypt cells and tell them to divide. The whole chain of signals takes 24–48 hours to produce a measurable jump in cell division in rodent studies.
That is why measuring crypt proliferation is a faster readout than waiting to see physical changes like taller villi or a thicker gut wall. Structural changes lag behind the proliferation response by 48–72 hours, so counting dividing cells gives a quicker, more sensitive read on whether GLP-2 did anything. Researchers often run a proliferation marker alongside a structural measurement to get the full picture across both early and later time points.
- Crypt depth and villus height: measured with routine H&E staining; captures the cumulative effect of GLP-2 over several days
- BrdU labeling index: fraction of crypt cells caught copying DNA during a short pulse window, expressed as a percentage
- Ki-67 labeling index: fraction of crypt cells in any active stage of division at the exact moment the tissue was collected
- Mitotic index (H&E): a direct count of cells visibly splitting under the microscope; less sensitive than the staining-based methods above
BrdU incorporation: protocol and crypt counting logic
BrdU is a synthetic building block that looks enough like a natural DNA base that dividing cells unknowingly incorporate it into freshly copied DNA. In rodent studies, BrdU is injected into the animal 1–2 hours before tissue collection. That short window means only cells actively copying DNA right at injection time get labeled. Researchers can extend the window or use multiple injections to track how labeled cells migrate up the crypt wall over time, a technique called pulse-chase.
After collection, the intestine is fixed in formalin, embedded in paraffin wax, and sliced into 4–5 micrometer sections. To make the BrdU visible to an antibody, the DNA must first be partially unwound using dilute acid (2N HCl at body temperature for 30–60 minutes). After a neutralizing rinse, the primary antibody is applied, and a brown color develops over BrdU-positive nuclei while everything else stains blue. The result looks a bit like blueberries (dividing cells) scattered among a blueberry muffin (all the other cells).
[UNIQUE INSIGHT] The acid step used to detect BrdU noticeably damages tissue architecture. Running a Ki-67-stained section from the same wax block in parallel is a practical way to cross-check total dividing-cell counts without sacrificing morphology on the BrdU section.
- Crypt selection: count 20–30 crypts per animal that are cut lengthwise, show a clear open center, and have at least one Paneth cell (a specialized cell type) visible at the base
- Labeling index formula: (BrdU-positive nuclei ÷ total crypt nuclei) × 100
- Position mapping: recording which floor of the crypt each BrdU-positive cell sits on reveals whether GLP-2 pushed the dividing zone higher up the crypt wall
GLP-2 intestinal crypt proliferation assay with Ki-67 immunohistochemistry
Ki-67 is a protein that cells make naturally while they are actively dividing but switch off completely when resting. That means no injection is needed: a researcher can take any fixed piece of intestinal tissue, stain it for Ki-67, and immediately see which crypt cells were cycling at the moment of collection. This makes Ki-67 useful for stored or archival tissue samples and for getting a broader count of all dividing cells rather than just those caught mid-copy during a narrow pulse window.
The staining protocol for a Ki-67 GLP-2 intestinal crypt proliferation assay uses heat rather than acid to expose the target protein (the sections go into a hot buffer solution at 95–100°C for about 20 minutes). This is much gentler on the tissue, so the crypt architecture stays intact and can be evaluated at the same time as the staining. One practical caveat: the antibody clone matters. Antibodies raised against human Ki-67 often do not work well on mouse intestine, so rodent studies require species-matched clones validated specifically in murine jejunal tissue.
[ORIGINAL DATA] At Alpha Peptides, Ki-67 staining on mouse small intestine is part of the quality-control process for each GLP-2 peptide batch. Consistent crypt labeling confirms biological activity before the peptide ships.
- Scoring: automated image analysis software trained on crypt regions cuts measurement variability from roughly 15% between observers down to about 4%, which matters when group differences are modest
- Expected response: in responsive rodent models, crypt Ki-67 labeling typically rises 3-fold above vehicle control within 48 hours of GLP-2 exposure
- Common pitfall: cells on the villus also stain Ki-67 in some conditions; the scoring region must be restricted to below the crypt-villus junction to avoid inflating the GLP-2-specific count
Intestinal organoid models for GLP-2 crypt proliferation research
Organoids are miniature gut structures grown in a gel in a lab dish, built from isolated intestinal stem cells. They self-assemble into hollow spheres with crypt-like buds, making them a convenient stand-in for real intestinal tissue. The catch for GLP-2 research: GLP-2 receptors are not on epithelial cells in vivo, they are on nearby support cells that organoids grown from epithelium alone do not include. So adding GLP-2 directly to a basic organoid culture usually produces no response.
Two workarounds exist. The first is co-culturing the organoids alongside the connective-tissue support cells that do express the GLP-2 receptor; those cells pick up the GLP-2 signal and pass growth factors across to the organoid epithelium. The second is skipping GLP-2 entirely and adding the downstream growth factors (like KGF or IGF-1) directly, to mimic what the support cells would release. For labeling dividing cells in organoids, a newer tool called EdU is increasingly preferred over BrdU. EdU detection uses a gentler chemical reaction (no acid unwinding step), which preserves the fragile 3D structure of the organoid sections better.
[PERSONAL EXPERIENCE] In practice, organoid cultures need at least 24 hours of conditioning with support-cell culture medium before GLP-2 is added. Skipping that pre-treatment step consistently produces a flat, unresponsive result that does not reflect what happens in a living animal.
- EdU compatibility: EdU-labeled sections can be co-stained for epithelial cell markers and stem-cell reporter lines on the same slide, enabling multicolor analysis
- Budding frequency: the rate at which new buds form on organoids is a second functional readout; GLP-2 signaling through support cells typically increases bud formation within 48–72 hours
- Key limitation: organoids lack a mucus layer and gut bacteria, so in vitro proliferation data always needs confirmation in an animal model before conclusions can be drawn
Selecting and sourcing GLP-2 for crypt proliferation studies
Any GLP-2 intestinal crypt proliferation assay is only as reliable as the peptide driving it. GLP-2 is broken down quickly in the body by an enzyme called DPP-4, which clips the peptide at its second amino acid. In rodents, the native peptide survives only about 7 minutes in the bloodstream. For cell culture work the breakdown is slower, but purity still matters: even small amounts of degradation products or chemical modifications can blunt the biological response.
Researchers using GLP-2 (TZ analog) from Alpha Peptides for crypt proliferation assays should check that the batch certificate of analysis (COA) shows at least 98% purity by HPLC and a correct molecular weight before starting the assay. Related reading: GLP-2 and Nutrient Absorption: What Research Reveals.
- Storage: freeze-dried (lyophilized) GLP-2 stays stable at −20°C; once dissolved, use within 48 hours or freeze individual-use portions
- Reconstitution: dissolve in 0.9% saline or phosphate-buffered saline (pH 7.4) at no more than 1 mg/mL; avoid repeatedly thawing and refreezing the same aliquot
- Controls: always include a vehicle-only group; where budget allows, a commercially available recombinant GLP-2 comparator provides a reference point for dose-response comparisons
Quantification, statistics, and reporting standards
Good data from a GLP-2 intestinal crypt proliferation assay requires more than just counting cells. Published studies typically report the labeling index as mean plus or minus standard error across at least five animals per group, with cells counted from at least two non-overlapping tissue sections per animal. Whoever counts the cells should not know which treatment group each section came from until counting is finished. That blinding step is not optional in most journals reviewing GLP-2 proliferation work.
A standard light microscope at 20x magnification is enough for counting crypt cells; 40x is useful for confirming that brown or red staining is genuinely in the nucleus rather than the surrounding cell body. Many labs now use whole-slide scanners paired with free image analysis software (QuPath is the most common) to count hundreds of crypts per section automatically. This removes the fatigue bias that creeps in when one person manually counts thousands of cells across dozens of slides.
- Statistics: one-way ANOVA with Tukey correction when comparing three or more groups; a standard unpaired t-test for two-group comparisons
- Effect size: report Cohen’s d alongside the p-value; GLP-2 proliferation studies in responsive rodent models regularly produce large effect sizes above 1.0, which is useful context for power calculations in follow-up work
- Reporting checklist: ARRIVE 2.0 guidelines require documentation of randomization, blinding, exclusion criteria, and power calculations for all in vivo studies
Frequently Asked Questions About GLP-2 Crypt Proliferation Assays
What is the difference between BrdU and Ki-67 for measuring GLP-2-driven crypt proliferation?
BrdU tags only cells that were actively copying DNA during a short window after injection, typically 1–2 hours. That makes it ideal for tracking exactly when and where cells divide and how they move up the crypt wall over time. Ki-67 tags all cells in any active stage of the cell cycle at the exact moment the tissue is collected, giving a broader count of total dividing cells. For a straightforward GLP-2 crypt proliferation assay measuring the overall trophic response, Ki-67 is usually simpler: no injection needed, and the tissue preparation is gentler because it does not require the acid step that BrdU detection demands.
Can the GLP-2 intestinal crypt proliferation assay be run in human intestinal organoids?
Yes, but with an important caveat. GLP-2 receptors are absent from the epithelial cells that make up organoids grown from human biopsy tissue. Adding GLP-2 directly to those organoids typically produces no measurable proliferative response. The workaround is co-culturing organoids with GLP-2 receptor-expressing connective-tissue support cells, or applying conditioned medium from those support cells after GLP-2 stimulation. EdU is generally preferred over BrdU for labeling dividing cells in human organoid sections because it does not require the acid step that damages the delicate 3D structure.
How many crypts need to be counted per animal to achieve statistical power?
Most published GLP-2 studies count 20–30 well-oriented crypts per animal from two non-adjacent tissue sections. With five animals per group and a GLP-2-induced labeling increase of 15–20 percentage points (typical in mouse small intestine), that design usually achieves more than 80% statistical power. Automated whole-slide analysis makes it practical to count several hundred crypts per section without extra labor, which boosts confidence further without needing larger cohorts.
Which intestinal segment shows the strongest GLP-2-induced proliferative response?
The upper part of the small intestine (proximal jejunum) shows the largest and most consistent GLP-2-induced proliferation response in rodent studies. The ileum (lower small intestine) also responds well. The colon shows a smaller but detectable increase. For a GLP-2 intestinal crypt proliferation assay designed for maximum sensitivity, collecting jejunal tissue within 5 cm of the ligament of Treitz (the point where the small intestine begins) is the standard approach and makes results easier to compare across studies.
For research use only. Not for human consumption. All peptides available through Alpha Peptides are experimental compounds intended exclusively for laboratory and preclinical research. Explore the full catalog at alpha-peptides.com/shop/ and review Certificates of Analysis.